GE · News · 20260913N
Acquisition / Partnership / Divestiture
GENERAL ELECTRIC CO · 2026-09-13 · Importance 52 · Surprise 42 · In source text
GE HealthCare is reportedly in talks to acquire Sofie Biosciences for approximately $1 billion. Sofie develops radiopharmaceutical agents and chemicals used in PET scans, including cancer detection applications involving gastro-oesophageal and pancreatic cancers. The transaction would strengthen GE HealthCare’s pharmaceutical diagnostics division and would be its second major acquisition since the 2024 separation from General Electric; no direct transaction impact on General Electric was reported.
Key facts
- GE HealthCare is reportedly in talks to acquire Sofie Biosciences for $1 billion. source
- This potential acquisition would be GE Healthcare's second-largest acquisition since its spin-off from General Electric. source
- If successful, this would be GE HealthCare's second major acquisition since its split from General Electric in 2024. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | contingent | -0.1% | GE HealthCare is reportedly in talks to acquire Sofie Biosciences for $1 billion. |
| assets | positive | contingent | +0.1% | GE HealthCare is reportedly in talks to acquire Sofie Biosciences for $1 billion. |